Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 200

Results For "NSE"

2388 News Found

Moderna working on HIV vaccine antigens delivered through mRNA technology
Biotech | January 28, 2022

Moderna working on HIV vaccine antigens delivered through mRNA technology

The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology


Minimizing API losses critical to responsible pharma manufacturing
News | January 27, 2022

Minimizing API losses critical to responsible pharma manufacturing

Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Mandaviya reviews public health preparedness to Covid-19
Policy | January 26, 2022

Mandaviya reviews public health preparedness to Covid-19

Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation


Polycarbin breaks the single-use scientific plastic mold
Sustainability | January 26, 2022

Polycarbin breaks the single-use scientific plastic mold

Closing the Loop on single-use plastics


Intellect closes US $10 m Series A to scale mental healthcare across Asia
Startup | January 26, 2022

Intellect closes US $10 m Series A to scale mental healthcare across Asia

The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners


Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
News | January 26, 2022

Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.

Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021


USFDA rejects Merck’s gefapixant; gain approval in Japan
News | January 25, 2022

USFDA rejects Merck’s gefapixant; gain approval in Japan

Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant


Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine
News | January 25, 2022

Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine

First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose


Eplontersen granted Orphan Drug Designation in the US
Biotech | January 24, 2022

Eplontersen granted Orphan Drug Designation in the US

The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US